Phase 3 GvHD Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD
cGVHD
Xuzhou Medical University20 enrolled1 locationNCT06244628
Recruiting
Phase 3
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Graft-Versus-Host-Disease (GVHD)
Incyte Corporation572 enrolled30 locationsNCT06615050
Recruiting
Phase 3
Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor
GvHD
Assistance Publique - Hôpitaux de Paris324 enrolled28 locationsNCT06083129
Recruiting
Phase 3
Use of Tocilizumab (TCZ) to prevent acute graft versus host disease (GVHD) randomized trial
Acute graft versus host disease (GVHD) post HLA-matched allogeneic haematopoietic progenitor cell transplantation (HPCT)
Royal Brisbane and Women's Hospital110 enrolled1 locationACTRN12614000266662